Last reviewed · How we verify
NCT07443306
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis
Phase 2 trial testing Flonoltinib Maleate in MF in 64 participants. Currently enrolling.
30 December 2027
Quick facts
| Lead sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 18 March 2026 |
| Primary completion | 30 December 2027 |
| Estimated completion | 30 March 2028 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Flonoltinib Maleate — full drug profile →
Conditions studied
- MF — all drugs for MF →
Sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd — full company profile →
Who can join
Adults 18 to 80, any sex, with MF. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial adopts a single arm, open label, multi center clinical trial design, with a planned enrollment of approximately 64 participants in the moderate to high risk MF trial who are refractory, relapsed, or intolerant to JAK inhibitor . Select successful trial participants and allocate flonoltinib maleate tablets based on platelet count levels during the screening period, qd,Oral administration on an empty stomach until the participants meet the withdrawal criteria.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07443306
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for MF
Currently open trials in the same condition.
- NCT07317700 — A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis · Phase 3 · recruiting
- NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
- NCT06479135 — Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp · Phase 3 · recruiting
Other Chengdu Zenitar Biomedical Technology Co., Ltd trials
Trials by the same sponsor.
- NCT07339748 — A Clinical Study of ZL-85FA Tablets · Phase 1, PHASE2 · not yet recruiting
- NCT07317700 — A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis · Phase 3 · recruiting
- NCT07193589 — A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis · Phase 2 · recruiting
- NCT07232290 — Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera · Phase 2 · recruiting
- NCT07011056 — A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07443306 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chengdu Zenitar Biomedical Technology Co., Ltd
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07443306.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing